Breaking Down AbbVie's Big Upgrade
Pharmaceutical spin-off AbbVie recently received a big upgrade from Wall Street bank Morgan Stanley, sending shares up 6% last week. In this video, health-care analyst David Williamson breaks down what investors need to know about this bullish report, and why they might want to show caution before buying AbbVie stock.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.
The article Breaking Down AbbVie's Big Upgrade originally appeared on Fool.com.David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid. The Motley Fool recommends Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.